A New Paradigm for the Treatment of Ovarian Cancer: The Use of Epigenetic Therapy to Sensitize Patients to Immunotherapy and Chemotherapy
Abstract
Our overall goal remains to bring epigenetic therapy to have major impact for the management of advanced ovarian cancer (OC). This past year, we continue to make exciting advances in our pre-clinical work and interim results from our leveraged clinical trial is pending now for low dose therapy targeting DNA demethylation paired with immune checkpoint therapy. Our two relevant studies of mouse models are now published, a study of aserous ovarian cancer in which we have identified that the demethylating agent, 5-aza-cytidine (AZA) potently stimulates tumor immune attraction of T-cells to the tumor microenvironment (PNAS, 2017). The treatment paradigm involves a newly regimen we first derived for addition of a histone deactylase inhibitor (HDACi) in a study of mouse models for lung cancer ( Cell, 2017). Further, we have just published work showing how an inhibitor of G9A, an enzyme mediating transcriptional repression, can augment the above AZA effects to induce the immune attraction parameters in OC cells ( Cancer Research, 2018). All of the above findings continue to document how epigenetic therapy can potentially improve immune checkpoint therapy for OC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2018
- Accession Number
- AD1095042
Entities
People
- Stephen B. Baylin
Organizations
- Johns Hopkins University